NASDAQ : NVAX
Novavax, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.08 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.66B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.66B |
| Enterprise Value | 1.24B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 164.95M |
| Shares Outstanding | 164.95M |
| Shares Change (YoY) | -3.06% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 58.89% |
| Float | 146.21M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.02 |
| Forward PS | 8.19 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.33 |
| Quick Ratio | 2.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.20 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -6.51% |
| Return on Invested Capital (ROIC) | -18.01% |
| Return on Capital Employed (ROCE) | -19.10% |
| Weighted Average Cost of Capital (WACC) | 17.22% |
| Revenue Per Employee | $552,465 |
| Profits Per Employee | -$330,748 |
| Employee Count | 749 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 41.92 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.42M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.72 |
| 52-Week Price Change | +20.29% |
| 50-Day Moving Average | 10.46 |
| 200-Day Moving Average | 9.30 |
| Relative Strength Index (RSI) | 44.88 |
| Average Volume (20 Days) | 9,130,718 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 47.35M |
| Short Previous Month | 46.05M |
| Short % of Shares Out | 28.71% |
| Short % of Float | 32.38% |
| Short Ratio (days to cover) | 5.77 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 413.80M |
| Gross Profit | -10.58M |
| Operating Income | -119.38M |
| Pretax Income | -245.32M |
| Net Income | -247.73M |
| EBITDA | -101.55M |
| EBIT | -119.38M |
| Loss Per Share | -$1.52 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 719.34M |
| Total Debt | 297.32M |
| Net Cash | 422.02M |
| Net Cash Per Share | $2.56 |
| Equity (Book Value) | -190.71M |
| Book Value Per Share | -1.16 |
| Working Capital | 440.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -36.90M |
| Capital Expenditures | -5.30M |
| Depreciation & Amortization | 17.83M |
| Net Borrowing | 80.66M |
| Free Cash Flow | -42.20M |
| FCF Per Share | -$0.26 |
Margins
| Measure | Value |
|---|
| Gross Margin | -2.56% |
| Operating Margin | -28.85% |
| Pretax Margin | -59.28% |
| Profit Margin | -59.87% |
| EBITDA Margin | -24.54% |
| EBIT Margin | -28.85% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 3.06% |
| Shareholder Yield | n/a |
| Earnings Yield | -15.06% |
| FCF Yield | -2.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.44 |
| Price Target Difference | 43.25% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -38.10% |
| EPS Growth Forecast (3Y) | -44.48% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.5 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |